BioSpace News Archive

OncoMyx Therapeutics, a privately-held oncolytic immunotherapy company, has extended its intellectual property (IP) portfolio to include an exclusive option to license IP rights for the use and delivery of myxoma virus to treat certain cancers from the University of Florida Research Foundation (UFRF)

RSIP Vision, a respected leader driving medical imaging innovation through advanced AI and computer vision solutions, announced today its new surgical workflow analysis technology, which can intelligently identify each separate stage of a surgical procedure and label them accordingly throughout the duration of the procedure.

Hyperfine, Inc., creators of the world’s first portable magnetic resonance imaging device, has named Scott Huennekens Executive Chairman of the Board.

BioProtect Ltd., a private commercial-stage medical device company, announced today that the company has enrolled all the planned patients in the ongoing IDE ProSpace™ trial, with a total of 222 patients recruited and randomized.

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it has entered a collaboration with the Joan & Sanford I Weill Medical College of Cornell University in the United States, to launch a phase II clinical study investigating the use of Kazia’s investigational new drug, paxalisib

A U.S. clinical trial of a COVID-19 rapid test approved by an institutional review board found the Specificity of confirmed negative Covid-19 patients by RT-PCR was 100% (95% CI, 88.4%-100.0%); meaning there was 100% agreement between a negative RT-PCR and negative Clungene® serological test result.

PYC Therapeutics, a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, announced residency at Johnson & Johnson Innovation, JLABS at San Diego after a successful application and selection process.

D&D Pharmatech, Inc., a clinical-stage biotechnology company focused on development and commercialization of revolutionary medicines, announced the appointment of Yoo-Seok Hong as Chief Executive Officer.

Attralus announced the presentation of clinical data for AT-01, a first-in-class pan-amyloid imaging agent, at the 2021 Society of Nuclear Molecular Imaging annual meeting by the company’s co-founder and interim Chief Scientific Officer, Jonathan Wall, PhD, a distinguished professor and director of the University of Tennessee Graduate School of Medicine’s Amyloidosis and Cancer Theranostics Program.

Mosaic ImmunoEngineering Inc. today announced the election of Robert A. Baffi, Ph.D., to Mosaic’s Board of Directors.